This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HGEN Humanigen (HGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Humanigen Stock (NASDAQ:HGEN) 30 days 90 days 365 days Advanced Chart Remove Ads Get Humanigen alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.06 million shsAverage Volume3.26 million shsMarket Capitalization$24,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHumanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More… Remove Ads Receive HGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter. Email Address HGEN Stock News HeadlinesFormer Humanigen director arrested for insider tradingDecember 25, 2024 | msn.comUS says former Humanigen chief scientific officer charged with insider tradingDecember 23, 2024 | reuters.comForget 99% of the entire stock market. Trade this one stock insteadJeff Clark says he joined the top 1% of wealthy Americans by doing something radically simple — ignoring 99% of the stock market and trading just one specific gold stock. He calls it the “One Gold Stock Retirement” strategy. Through bull and bear markets alike, he’s used this same trade to rack up triple-digit gains — often outperforming gold itself. And he's not the only one: over 20,000 everyday investors have tapped into this approach to pursue financial freedom. Whether you’re starting with $100 or $1 million, this monthly trade could help you profit in any market — even during crashes.April 4, 2025 | InvestorPlace (Ad)Humanigen, Inc. (HGEN)October 10, 2024 | finance.yahoo.com0KB1.SG,0P00011RKD,0 (0KB1.SG)August 4, 2024 | ca.finance.yahoo.comHumanigen Inc (0KB2.BE)March 24, 2024 | finance.yahoo.comHumanigen Inc HGENQFebruary 6, 2024 | morningstar.comLevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementJanuary 25, 2024 | markets.businessinsider.comSee More Headlines HGEN Stock Analysis - Frequently Asked Questions How were Humanigen's earnings last quarter? Humanigen, Inc. (NASDAQ:HGEN) issued its quarterly earnings data on Friday, November, 12th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.14. The firm had revenue of $1.04 million for the quarter, compared to the consensus estimate of $0.40 million. When did Humanigen's stock split? Shares of Humanigen reverse split on the morning of Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Humanigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humanigen investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA). Company Calendar Last Earnings11/12/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HGEN CIK1293310 Webwww.humanigen.com Phone650-243-3100FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.70 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / BookN/AMiscellaneous Outstanding Shares119,080,000Free Float93,240,000Market Cap$24,000.00 OptionableNo Data Beta-1.04 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:HGEN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humanigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humanigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.